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Scars: A New Point of View in 
Plastic Surgery
Gustavo E. Prezzavento
Abstract
The issue of achieving esthetically pleasing surgical scars has gained prominence 
in recent years, with the emergence of the concept of the “imperceptible scar,” 
which is expected by patients of not only cosmetic but also reconstructive surgery. 
Current research in reconstructive surgery focuses on obtaining high-quality results 
in the minimum number of steps, with a view to “doing it right the first time.” 
However, there is no uniform approach to scar treatment, which is partly due to a 
lack of consensus regarding the most effective healing methods. This chapter aims 
at shedding new light to discussion by putting forward two different procedures 
that enhance scar results in cosmetic and reconstructive surgeries by applying a 
topical treatment with active ingredients and by combining cadaver and artificial 
skin as dermal substitutes, respectively. The effectiveness of these treatments is 
shown by means of objective, quantifiable data collected as a result of studies and 
postoperative follow-ups carried out at Hospital Alemán in Buenos Aires.
Keywords: scars, surgical wound, wound healing, reconstructive surgery, 
esthetic surgery
1. Introduction
Scars are a natural part of dermal healing following lacerations, incisions, or tis-
sue loss. Wound healing, which is a natural process of tissue repair, consists of three 
phases: inflammation, fibroplasia, and maturation. The healing tissue generates 
changes in the cutaneous architecture, which renders the skin surrounding the scar 
different from the rest of the skin in terms of color, thickness, elasticity, texture, and 
degree of contraction [1]. In surgical procedures, scars, which are the only visible 
sequela of the intervention, result from the reparation process undergone by the skin 
to heal the wounds caused by surgery or trauma. Because of its impact in scarring, 
considerable importance is placed on the closure of a surgical incision, which is the 
final phase of the intervention [2]. The ideal scar is narrow, flat, level with sur-
rounding tissue, and difficult for the untrained eye to see due to color match and 
placement parallel to relaxed skin tension lines. In contrast, hypertrophic, keloidal, 
dyspigmented, widened, contracted, or atrophic scars can be unsightly and/or cause 
functional limitations, which patients often perceive as a problem.
Thus, when the scar has unfavorable characteristics, scar revision is often 
indicated. Furthermore, as poor-quality healing of an incision can constitute a 
disabling pathology [3], scar treatment should not be considered as a trivial part of 
the intervention. On the contrary, wound treatment and care after surgery of any 
kind, including esthetic or reconstructive interventions, should be initiated early. 
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In order to arrive at an effective esthetic and functional outcome, surgeons must be 
familiar with the different scar treatments available, and they must also know how 
to prevent scars and how to reduce them after surgery. In this sense, it should be 
borne in mind that, while there exist multiple treatment modalities, none of them 
guarantees a 100% success rate. Current guidelines suggest a multimodal approach 
to treating scars but there is no gold standard for their treatment. In this chapter, we 
will present two new ways to treat scars following plastic surgery. As explained in 
the following sections, these techniques were successfully implemented in a number 
of cases, and their comparative advantages regarding other methods were also 
evaluated. We hope that our contribution will help point in the direction toward an 
effective, uniform standard.
The first part of our research deals with cosmetic surgery scars, which gener-
ally receive different topical treatments that help maintain the moisture and the 
plasticity of the wound. Besides, these treatments prevent wound contamination or 
infection, which would delay healing. We have analyzed and compared the results 
of two of these treatment options and found that the best functional and esthetic 
results are obtained when using a cream with active ingredients. The second part 
of our research revolves around the combined use of two skin substitutes, cadaver 
skin and artificial skin, so as to obtain improved results in reconstructive surgery 
after trauma injuries with abnormal wound healing in response to skin trauma or 
inflammation. Employing dermal substitutes result in a better regeneration of the 
dermis and in dermal fibroblast optimization. In the next sections, we will present 
a detailed account of the two studies we have carried out, which will allow us to 
further discuss the aforementioned techniques to optimize surgical scars.
2. Topical treatment of cosmetic surgery scars
As we have already mentioned, the first study involved the comparison and 
evaluation of two topical treatments applied to scars resulting from cosmetic sur-
gery. One was a cream containing 1 g of silver sulfadiazine, 248,000 IU of vitamin 
A and 0.666 g of lidocaine in each 100 g of product (Platsul-A®, Soubeiran Chobet 
Laboratory, Autonomous City of Buenos Aires, Argentina) (cream A), and the 
other was a moisturizing cream based on petrolatum, keto-stearyl alcohol, glycerin, 
and water without any active ingredient (cream B). About 32 patients participated 
in the study; 24 with bilateral breast implants and 8 with face and neck lifts, hence 
totaling 64 scars. The study included patients of both sexes: 31 women and 1 man, 
with ages ranging from 22 to 64 years (mean of 41 years). All patients received 
both topical treatments under study, each of their postsurgical scars (right and left) 
being applied one of the creams at random. We monitored patients for 1 month 
after the beginning of treatment, meeting them at an initial appointment and at 
subsequent appointments after 3, 6, 9, 16, 23, and 30 days from the intervention. 
Each patient’s progress was checked by the same medical examiner.
In these appointments, we measured the length and width of the scars to 
determine their total surface and assessed them in accordance with the Vancouver 
scar scale (VSS) and the patient and observer objective assessment scale (POSAS). 
We evaluated (1) the surface area of each scar by multiplying its length by its width, 
as measured with a ruler with graduation, (2) the quality of each scar as assessed 
by the VSS, [4] taking into account the parameters of pigmentation, vascularity, 
and thickness, and (3) the patient’s perception of each scar as appraised by the 
POSAS, [5] by having them rank a series of symptomatic and esthetic parameters. 
The results are reported as follows, discriminated on the basis of the type of surgery 
performed.
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2.1 Surface area of each scar
In the group of patients with breast implants, the percentage of change did not 
differ significantly between the two treatments studied in the appointments of 
days 3, 6, 9, 16, and 23. On day 30, however, we detected a statistically significant 
difference (P = 0.017). The percentage of decrease was significantly higher in the 
scars treated with the cream with silver sulfadiazine, vitamin A, and lidocaine 
(cream A) than in those treated with the cream without active ingredients (cream B)  
(18.6 and 9.5%, respectively) (Table 1). In the group of patients with face and 
neck lift, there was no significant difference between the percentage of change 
achieved due to the two treatments on days 3, 6, 9, and 16. Nevertheless, on days 
23 and 30, we encountered a statistically significant difference (P = 0.026 and 
P = 0.007, respectively). The percentage of decrease was significantly higher in 
the scars treated with cream A than in those that had been treated with cream 
B. On day 23, the surface area of the scars treated with cream A had decreased, on 
average, by 14.8%, while that of the scars treated with cream B had increased, on 
average, by 24.9%. On day 30, the surface area of the scars treated with cream A 
had decreased, on average, by 19.1%, whereas that of the scars treated with cream 
B had increased, on average, by 22.2% (Table 2). Figure 1 shows the changes in 
the surface area of each patient’s scars on days 23 and 30 with respect to the initial 
appointment and classifies the results according to the type of surgery undergone 
and the treatment received. As we can see, more favorable results were obtained 
with cream A than with cream B, except in the case of two patients with breast 
implants (patients No. 7 and 12).
2.2 Vancouver scar scale
The VSS assigns values to the scar pigmentation, vascularity, and thickness, 
which are then added to obtain a total. Although the score may vary between 0 
and 10, the average of the initial scores in our study was 2.7 and the maximum 
value observed throughout the study was 5. We conducted the analysis taking into 
account the absolute change in the VSS score with respect to the initiation of treat-
ment (day 0). Results are expressed in absolute values. The analysis is carried out 
separately for each group of patients, depending on the type of surgery, on days 3, 
6, 9, 16, 23, and 30.
In the breast implant patient group, the VSS score change did not differ signifi-
cantly between treatments on days 3, 6, 9, and 16. On days 23 and 30, nonetheless, 
Days Average percentage of change of the surface area as from treatment onset 
(breast implant)
P
Cream A (%) Cream B (%)
3 4.2 0.0 0.97 (NS)
9 2.6 3.7 0.37 (NS)
16 −1.8 −6.0 0.40 (NS)
23 −12.8 −7.2 0.089 (NS)
30 −18.6 −9.5 0.017*
NS: not significant.*Significant: at 5%.
Table 1. 
Average percentage of change of the surface area of the scars treated with silver sulfadiazine, vitamin A, and 
lidocaine (cream A) and with a cream without active ingredients (cream B) in patients with breast implants 
after 3, 6, 9, 16, 23, and 30 days from the onset of the topical treatment.
Scars
4
we noticed a statistically significant difference (P = 0.02 and P = 0.006, respec-
tively). The decrease was significantly higher in the scars treated with cream A 
in comparison with those treated with cream B. On day 23, the score of the scars 
treated with cream A decreased by 1.13 points average, while that of the scars 
treated with cream B increased by 0.04 points average. On day 30, the average score 
decrease was of 1.88 points in those treated with cream A and of 0.42 points in 
those treated with cream B (Table 3).
In the group of patients with face and neck lift, the change in the VSS score did 
not differ significantly between treatments after 3 days. Yet, in all of the following 
appointments, a statistically significant difference (P ˂ 0.05) was observed. The 
reduction of the score was significantly higher in scars treated with cream A than in 
Figure 1. 
Percentage changes of the scar surface area, per patient after 23 and 30 days from treatment onset.
Days Average percentage of change of the surface area as from treatment onset 
(face and neck lift)
P
Cream A (%) Cream B (%)
3 12.5 12.5 +
6 12.5 12.5 +
9 12.3 12.4 0.60 (NS)
16 2.1 24.9 0.07 (NS)
23 −14.8 24.9 0.026*
30 −19.1 22.2 0.007**
NS: not significant. 
*Significant at 5%.
**Significant at 1%.
+No surface area changes were perceived in any patient in either of the treatments.
Table 2. 
Average percentage of change of the surface area of the scars treated with silver sulfadiazine, vitamin A, and 
lidocaine (cream A) and with a cream without active ingredients (cream B) in patients with face lift after 3, 6, 
9, 16, 23, and 30 days from the onset of the topical treatment.
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those treated with cream B. On day 23, scars treated with cream A had decreased by 
0.86 points average, while those treated with cream B had increased by 1.75 points 
average. On day 30, the average score decrease of scars treated with cream A was 
1.88 points, while the score of scars treated with cream B increased by 1.88 average 
points (Table 4). Figure 2 displays the changes in the VSS scores for each patient 
with breast implants on 23 and 30 days, compared to the initial control. In a major-
ity of patients, we see a favorable effect with the cream A treatment compared to 
cream B, except for three cases (patients No. 16, 28, and 30). Figure 3 illustrates the 
changes in the VSS scores for each patient with face and neck lifts on days 6, 9, 16, 
23, and 30 with respect to the initial appointment. In most cases, cream A shows a 
more favorable effect in comparison with cream B. Regardless of whether cream A 
or B had been used, in general, the changes observed in the VSS, either increase or 
decrease, were homogeneous in the three variables that make up this scale: pigmen-
tation, vascularity, and thickness of the scar. Figures 4–6 illustrate the different 
results obtained when applying each cream.
Days Average change in the VSS score as from treatment onset (breast implant) P
Cream A Cream B
3 0.33 0.21 0.80 (NS)
6 0.13 0.29 0.30 (NS)
9 −0.21 0.46 0.10 (NS)
16 −0.42 0.29 0.09 (NS)
23 −1.13 0.04 0.02*
30 −1.88 −0.42 0.006**
VSS: Vancouver scar scale.
NS: not significant. 
*Significant at 5%.
**Significant at 1%.
Table 3. 
Average change in the VSS score of scars treated with silver sulfadiazine, vitamin A, and lidocaine (cream A) 
and with a cream without active ingredients (cream B) in patients with breast implants after 3, 6, 9, 16, 23, 
and 30 days from the onset of the topical treatment.
Days Average change in the VSS score as from treatment onset (face and neck lift) P
Cream A Cream B
3 0.50 1.50 0.17 (NS)
6 0.13 1.50 0. 048*
9 −0.13 2.00 0.029*
16 −0.50 1.88 0.029*
23 −0.86 1.75 0.020*
30 −1.88 1.88 0.007**
VSS: Vancouver scar scale.
NS: not significant. 
*Significant at 5%.
**Significant at 1%.
Table 4. 
Average change in the VSS score of scars treated with silver sulfadiazine, vitamin A, and lidocaine (cream A)  
and with a cream without active ingredients (cream B) in patients with face lift after 3, 6, 9, 16, 23, and 
30 days from the onset of the topical treatment.
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2.3 Patient and observer objective assessment scale
This scale allowed us to evaluate numerically, based on the patient’s own 
answers, scar characteristics related to pain, itching, color, stiffness, and thickness. 
The treating physician recorded the data reported for each variable and for each 
scar during the corresponding appointments. Although the score may vary between 
0 and 60, the average of the initial scores was 16 and the maximum value observed 
throughout the study was 25. We carried out the analysis taking into account the 
Figure 2. 
Changes in VSS scores for each patient with breast implants after 23 and 30 days from treatment onset of 
treatment. VSS: Vancouver scar scale.
Figure 3. 
Changes in VSS scores for each patient with cervical-facial stretch and after 6, 9, 16, 23, and 30 days from 
treatment onset. VSS: Vancouver scar scale.
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percentage change in the score of the scale with respect to that of the beginning 
of the treatment (day 0). We evaluated the results separately for each group of 
patients, depending on the type of surgery performed, and we considered the 
results obtained on days 3, 6, 9, 16, 23, and 30 of the postoperative period.
In the group of patients with breast implants, the percentage change of the 
score of the POSAS did not differ significantly between the treatments on days 3 
and 6, but in the remaining appointments, we found a statistically significant 
difference (P < 0.05) in favor of cream A. The percentage decrease in the score 
was significantly higher in those scars treated with cream A than in those treated 
with cream B. On day 23, the score of scars treated with cream A decreased by 
Figure 4. 
Same patient’s evolution with cream A (left) versus cream B (right) following a breast implant intervention 
(submammary incision).
Figure 5. 
Same patient’s evolution with cream A (left) versus cream B (right) following a face lift intervention.
Figure 6. 
Same patient’s evolution with cream A (left) versus cream B (right) following a breast implant intervention 
(periareolar incision).
Scars
8
21.8 points average, while that of the scars treated with cream B did so by 1.3 points 
average. On day 30, the average score decrease was of 37.7 points in scars treated 
with cream A while, in those treated with cream B, the decrease was 7.3 points 
average (Table 5).
In the group of patients with face and neck lifts, the percentage change in the 
POSAS score did not differ significantly between the treatments on days 3, 6, 9, 16, 
and 23. On day 30, however, we detected a statistically significant difference  
(P = 0.021) in favor of cream A. The percentage decrease was significantly higher in 
cases treated with cream A versus those treated with cream B. On day 30, the score 
of scars treated with cream A decreased, on average, by 14.4%, while that of the 
scars treated with cream B increased, on average, by 26.6% (Table 6). Figure 7  
presents the percentage changes of the POSAS scores for each patient with 
breast implants on days 9, 16, 23, and 30 with respect to the initial appointment, 
Days Average change in the POSAS score as from treatment onset (face and neck 
lift)
P
Cream A Cream B
3 2.5 8.5 1.0 (NS)
6 1.7 7.8 0.129 (NS)
9 −6.2 7.1 0.026*
16 −9.9 6.6 0.037*
23 −21.8 −1.3 0.005**
30 −37.7 −7.3 0.0007**
POSAS: patient and observer scar assessment scale.
NS: not significant. 
*Significant at 5%.
**Significant at 1%.
Table 5. 
Average POSAS score change rate for scars with silver sulfadiazine, vitamin A, and lidocaine (cream A) and 
with a cream without active ingredients (cream B) in patients with breast implants after 3, 6, 9, 16, 23, and 
30 days from the onset of the topical treatment.
Days Average change in the POSAS score as from treatment onset (breast implant) P
Cream A Cream B
3 22.1 18.2 0.66 (NS)
6 18.2 20.2 0.40 (NS)
9 19.0 26.3 0.26 (NS)
16 18.0 23.9 0.36 (NS)
23 −1.4 32.7 0.07 (NS)
30 −14.4 26.6 0.021*
POSAS: patient and observer scar assessment scale.
NS: not significant.
*Significant at 5%.
Table 6. 
Average POSAS score change rate for scars with silver sulfadiazine, vitamin A, and lidocaine (cream A) and 
with a cream without active ingredients (cream B) in patients with face lift after 3, 6, 9, 16, 23, and 30 days 
from the onset of the topical treatment.
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differentiated according to the treatment applied. In most patients, we see that the 
treatment with cream A resulted in a more favorable effect than that obtained with 
cream B, except for two cases (patient No. 15, days 9 and 16; and patient  
No. 13, day 16). Figure 8 shows the percentage changes of the POSAS scores for each 
patient with face and neck lift between the onset of the treatment and day 30 and 
organizes the results based on the cream employed. In most cases, a better outcome 
was reached with cream A than with cream B. Irrespective of the cream applied, in 
general, the changes observed, either increase or decrease, reflected homogeneous 
changes in the variables that constitute this scale.
Figure 7. 
Percentage POSAS score changes for each patient with breast implants after 9, 16, 23, and 30 days from the 
beginning of treatment. POSAS: patient and observer objective evaluation scale.
Figure 8. 
POSAS score changes for each patient with face lift after 30 days from treatment onset. POSAS: patient and 
observer objective evaluation scale.
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The results showed an improvement of all the evaluated variables when 
we used the cream with silver sulfadiazine, vitamin A, and lidocaine as treat-
ment [6]. In all the scars treated in this way, we observed a greater percentage 
decrease of the surface area as compared with those treated with the cream 
without active principles. In addition, the scars treated with silver sulfadiazine, 
vitamin A, and lidocaine obtained a lower POSAS score, associated with a better 
scar quality. Such decrease in the POSAS score throughout the treatment is 
indicative not only of a more positive perception by the patient of the healing 
process but also of improvement of all the parameters evaluated: pain, itching, 
color, stiffness, thickness, and irregular scarring [7]. Therefore, our results 
indicate that performing a topical treatment with a cream containing silver sul-
fadiazine, vitamin A, and lidocaine from the beginning of treatment decreases 
wound size faster, improves the quality of the scar and the overall perception 
of the patients. In other words, such a treatment of postcosmetic surgery scars 
yields better esthetic and functional outcomes [8].
3. Combining skin substitutes for dermal reconstruction
The other treatment we are concerned with involves using different dermal sub-
stitutes in reconstructive surgery. Soft tissue impairment after an accident requires 
fast radical treatment and often multiple surgical procedures related to necrotic 
and poorly perfused tissue. Traditionally, dermal reconstruction meant harvest-
ing grafts and flaps, which left major sequelae in donor sites. However, modern 
understanding of the composition of the skin has enabled researchers to develop 
numerous cutaneous substitutes which allow for the reconstruction of the dermis 
by providing a scaffold that promotes new tissue growth, thus compensating for 
the functional and physiological impairments caused by damaged tissue. Moreover, 
they offer the attractive possibility of employing grafts to treat large burns.
Skin substitutes are biomatrices that may be used to replace the damaged epidermis 
or dermis (or both) partially or totally, transitory or definitively. Although they can be 
classified in different ways [9], they fall broadly into two groups, either decellularized 
dermis derived from human or animal sources or artificially constructed scaffolds 
comprised of highly purified biomaterials or synthetic polymers. Many of these sub-
stitutes act by guiding the patient’s own cells to form a neodermis, both reducing pain 
and improving healing by avoiding excessive scarring [10]. They allow practitioners to 
create a controlled environment appropriate for physiology and cellular function, as 
well as to identify and properly manipulate the cells so that parenchyma, stroma, and 
vascular components are generated, and to produce materials malleable by the cells.
One such cutaneous substitute is Integra®, which consists of a matrix of purified 
collagen from bovine tendon cross-linked with glycosaminoglycan obtained from 
shark cartilage and a silicone layer that functions as a temporary epidermis. It is 
a bilayer membrane system, consisting of an inner dermal substitute layer and a 
temporary outer epidermal substance layer. The inner layer is composed of a three-
dimensional matrix of cross-linked bovine tendon collagen plus a glycosaminogly-
can, and the outer layer is made of silicone. Integra® was introduced by Burke and 
Yannas in the early 1980s. The aim of their research was to find a substitute for the 
skin of patients with massive burns [11]. Nowadays, Integra® is a fundamental part 
of the “reconstructive ladder” and is utilized for treating skin loss resulting from 
burns, trauma and oncologic and pressure sore surgery [12]. After application of 
Integra®, the patient’s native fibroblasts, macrophages, and lymphocytes infiltrate 
and new capillary growth occurs into the matrix of the inner layer. The inner layer 
becomes degraded and an endogenous collagen matrix is deposited by the patient’s 
11
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own fibroblasts, forming a neodermis. Once engraftment is complete, 2–3 weeks 
after application, the outer silicone layer needs to be removed and an epidermal 
autograft must be placed over the neodermis. One of the advantages of this process 
is that successful neodermis formation requires only a thin skin graft which pro-
vides epidermal coverage which also prevents infections. Furthermore, as no donor 
site is created, it eliminates the risk of donor site wound complications.
Another skin substitute is cadaver skin or homograft, which was included in 
protocols for the first time in the year 1981 in Philadelphia, United States. By virtue of 
the processing of cadaver skin through a skin bank, a suitable substitute is obtained 
and distributed to potential receptors [13]. Depending on the way in which they are 
processed, these “acellular dermal homografts” (as Takami describes them [14]) 
can be used transiently or permanently. To reduce the probability of graft rejection, 
cadaveric grafts undergo a cell-removal process and the resulting acellular tissue is 
irradiated with gamma rays, which destroy the immunogenic potential of the tissue. 
Employing cadaver skin to treat severe trauma of lower limbs with skin impairment 
has a number of advantages. To begin with, this treatment produces a biological 
closure after escharectomy. Furthermore, it helps reduce the loss of fluids, proteins, 
and electrolytes, as well as the pain experienced by the patient. Apart from this, it 
prevents the desiccation of the wound bed, since it functions as a biological cover 
for complex wounds, ultimately improving the preparation of the wound bed before 
definite reconstruction [15]. Finally, the addition of artificial skin over the vascular-
ized homologous dermis creates a dermal structure of greater thickness and elasticity.
Another recent development which is of great importance for reconstructive 
surgery is vacuum therapy (VAC), which improves wound healing by means of 
two main mechanisms. In the first place, it acts on the interstitial level eliminating 
edema, inflammatory mediators, and bacteria. It thus combats the vicious cycle of 
increased interstitial edema and pressure, cell death, and necrosis which is begot-
ten by the inflammatory response triggered after a lesion. In addition, this treat-
ment promotes mitogenesis and granulation tissue formation [16]. VAC is relevant 
to our research since, as Morykwas explains, it can be used to help incorporate 
Integra® and skin grafts as permanent replacements. Using a vacuum system after 
the escharectomy and the homograft placement and 1 week after positioning the 
artificial skin and the ultrathin autograft favors the arrest of these two substitutes. 
Moreover, negative pressure wound therapy can help augment the healing process 
and prepare the wound for definitive closure. A review published in Cochrane in 
2007 [21] reported that, after 6 months of treatment, a 71% success rate had been 
observed in wounds treated with both artificial skin and negative pressure through 
Figure 9. 
Full-thickness trauma in lower limbs.
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Figure 11. 
(1) Escharectomy, (2) cadaver skin, (3) vacuum system, (4) epidermolysis, (5) neovascularized homodermis, 
and (6) artificial skin over vascularized homodermis—final result with autograft.
a vacuum system, whereas the success rate of wounds treated solely with negative 
pressure had been, at 37%, significantly lower. In terms of wound healing, even 
better results were obtained when Integra® was used as a dermal substitute [22].
As a consequence of the benefits we have mentioned, dermal substitutes have now 
been extended to treat other pathologies. Furthermore, the use of cutaneous substi-
tutes added to the vacuum therapy has been incorporated into the “Modified Ladder of 
Reconstruction” [17]. However, the usefulness of treating large wounds with deep skin 
impairment with both cadaver skin and artificial skins has not been, to date, exhaus-
tively studied. Therefore, we wish to contribute to this line of research by reporting the 
successful esthetic and functional results we have obtained when treating extensive 
skin lesions with both substitutes. Our study involved the follow-up of the wound 
healing of four patients (N:4) who had suffered high impact trauma in their lower 
Figure 10. 
Pulaski and Tennison’s Rules of Nines.
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limbs (Figure 9) and who were treated at Hospital Alemán in the city of Buenos Aires. 
All of them were females with ages ranging from 19 to 73 years (median: 32 years). All 
of their lesions belonged to Group 4 of Benaim’s severity classification and ranked as 
full-thickness burns in Benaim’s depth classification [18]. The affected body surface 
was calculated based on the rule of nines described by Pulaski and Tennison in 1949 
[19] (Figure 10) with the following results: 8% in the 19-year-old patient, 24% in the 
22-year-old, 28% in the 43-year-old, and 8% in the 73-year-old (Table 4).
In all cases, escharectomy was performed on fascia within the first 48 h of the 
accident. Immediately afterward, the wounds were covered with cadaver skin from 
the tissue bank. Over the next 5–9 days, epidermolysis was observed (i.e., spontane-
ous removal of the epidermis), as well as vascularization and arrest of the homolo-
gous dermis on the receptor bed. In the second stage, the artificial skin was placed 
on the built-in vascularized homologous dermis. Once the artificial skin had been 
placed, we waited for 21 days before removing the silicone layer and completing the 
third and last surgical stage with the placement of a 1/4-thick autograft, obtained 
with an electric dermatome, over the heterologous vascularized neodermis. Figure 11 
illustrates the procedure we followed and the results we obtained.
We used a grid of manual design to evaluate the arrest of the cadaver and artificial 
skin (expressed in percentages). The arrest of the cadaver skin was of 95% and the 
placement of the heterologous matrix with an ultrathin autograft was of 94%. The 
average hospital time was 46 days. No major complications were present, but only 
minimal difficulties belonging to grades 3b, 4, and 5 of the Dindo and Clavien table 
[20] (Table 7). After a year of follow-up, we observed that favorable functional results 
had been obtained in highly complex articular areas such as ankles or knees due to the 
contribution of homologous and heterologous matrixes that provided adequate scaf-
folding. With respect to the esthetic results, no depression of the covered surfaces was 
observed with respect to the adjacent normal dermal tissue. Furthermore, there was no 
evidence of pathological scarring (such as keloids or hypertrophic scars).
Grade Definition
Grade 1 Any deviation from the normal postoperative course without the need for pharmacological 
treatment or surgical, endoscopic, and radiological interventions
Allowed therapeutic regiments are: drugs and antiemetics, antipyretics, analgetics, diuretics, 
electrolytes, and physiotherapy. This grade also includes wound infections opened at the 
bedside
Grade 2 Requiring pharmacological treatment with drugs other than such allowed for grade 1 
complications. Blood transfusions and total parenteral nutrition are also included
Grade 3 Requiring surgical, endoscopic, or radiological intervention
Grade 3a Intervention not under general anesthesia
Grade 3b Intervention under general anesthesia
Grade 4 Life-threatening complications including brain hemorrhage, ischemic stroke, subarachnoid 
bleeding, and central nervous system complications (but excluding transient ischemic 
attacks) requiring intermediate care or intensive care unit management
Grade 4a Single organ dysfunction (including dialysis)
Grade 4b Multiorgan dysfunction
Grade 5 Death of a patient
Suffix “d” If the patient suffers from a complication at the time of discharge, the suffix “d” (for 
“disability”) is added to the respective grade of complication. This label indicates the need for 
a follow-up to fully evaluate the complication
Table 7. 
Dindo classification of surgical complications.
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4. Conclusions
The goal of any healing process is not only that the scar does not bring about func-
tional disruptions, but also that it is as inconspicuous as possible. Patients of both cos-
metic and reconstructive surgery expect scars that do not stand out from the normal 
surrounding skin, yet there is no consensus among medical practitioners as to which 
healing methods can achieve both functional and esthetic goals most effectively. In 
this chapter, we have accounted for two studies carried out at Hospital Alemán in the 
city of Buenos Aires, the promising results of which may help practitioners arrive at a 
standard for treating scars resulting from cosmetic and reconstructive surgery.
Regarding postcosmetic surgery scars, we have tested the progress of the scars of 
32 patients, each having two postsurgical scars that were treated with two differ-
ent creams. The results of our research show that performing a topical treatment 
with a cream that contains silver sulfadiazine, vitamin A, and lidocaine from the 
onset of the treatment decreases the size of the wound more quickly, improves the 
quality of the scar and the patient’s perception of it. These findings contrast with 
the less positive outcome of the scars treated with a moisturizing cream without 
active ingredients [23]. Thus, we conclude that using creams with active ingredients 
should be promoted as a common practice.
In turn, in our study related to reconstructive surgery, we followed the progress 
of four patients whose massive skin loss was treated with a combination of artificial 
and cadaveric dermal substitutes. Using modern biotechnology to reconstruct 
damaged structures and to provide a new extracellular matrix constitutes the 
greatest breakthrough in reconstructive surgery of recent times. The development 
of homografts and artificial skin has allowed professionals to accelerate healing 
by covering wounds transitorily or permanently. At the same time, they work as a 
barrier against infections, help maintain the hydroelectrolytic balance [24], and 
improve esthetic and functional results. As we explained in the previous section, 
the quality of the scar and the properties of the neodermis depend on the use of an 
appropriate extracellular matrix [25].
As part of our research, we assessed the progress of the four patients’ scars, focus-
ing on such characteristics as color, thickness, volume, and pain, as well as on the 
restoration of function at affected sites. We noted positive outcomes in all evaluated 
parameters, which points at the advantages entailed in implementing this technique. 
Moreover, the number of hypertrophic scars was lower than the average. Our method 
fulfilled the ultimate goal of tissue engineering, namely, to restore damaged or lost tis-
sue in traumatic wounds that result in a functional barrier, providing, at the same time, 
for rapid closure to prevent dehydration and bacterial infection. As attested by our 
results, the advantages of combining both dermal substitutes include better functional 
and esthetic outcomes, pain relief, and enhancement of the overall quality of the scar.
All in all, the results of both studies are indicative of the direction that modern scar 
treatment can take in order to achieve the desired goals in both cosmetic and recon-
structive surgery. In the case of the former, achieving an esthetically pleasing scar has 
long been recognized as a fundamental requirement of a successful intervention. Here, 
the most optimal results can be achieved if wound treatment and care are initiated 
early. However, the esthetic factor should not be limited to this type of procedures. 
Our work on reconstructive surgery centers around the concept that such surgery 
should not only merely aim at “rebuilding” but also at obtaining the best functional 
and esthetic outcome with the least possible number of interventions. Recent advances 
in biotechnology offer us effective skin substitutes, which can be combined so as to 
achieve a better evolution of the wounds. [26] Such improved esthetic and functional 
results in posttraumatic reconstructive surgery ensure an ad integrum recovery of the 
affected areas, which, ultimately, enhances the quality of patients’ lives.
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